18.71MMarket Cap
LossP/E TTM
Key Figures
--Open
0.000High
0.00Volume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.28%Turnover Ratio
28.560Prev. Close
0.000Low
0.00Turnover
LossP/E Static
38.66P/B
0.00%Div Yield TTM
-52.78%ROA
1.96052wk High
0.04Volume Ratio
-39.83MNet Profit
33.35MShares
-0.5012EPS TTM
2.01Beta
-63.16%ROE
0.28152wk Low
1019.65%Amplitude
100.00%Gross Margin
18.71MMarket Cap
10.56Reward/Risk
3.71%Risk Rate
Currency: USD Updated: 2026-07-27 Key Insights
Vyne Therapeutics Inc's fundamentals are relatively very healthy, and its growth potential is significant.Its valuation is considered fairly valued, ranking 58 out of 386 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 2.00.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Vyne Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Vyne Therapeutics Inc Highlights
StrengthsRisks
Vyne Therapeutics Inc News
More news coming soon, stay tuned...
Earnings Forecast
Strong Buy
Buy
Hold
Sell
Strong Sell
Vyne Therapeutics Inc
VYNE
0
Ionis Pharmaceuticals Inc
IONS
25
Indicators
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Vyne Therapeutics Inc Info
VYNE Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need. Its lead program is repibresib gel (also known as VYN201), a topically administered, small-molecule pan-BD bromodomain and extra-terminal (BET) inhibitor designed as a soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways while providing low systemic exposure. Its second program is VYN202, an oral, small-molecule BD2-selective BET inhibitor. The Company has rights to research, develop and commercialize products containing BET inhibitor compounds for the treatment of any disease, disorder or condition in humans. Utilizing its InhiBET platform and through its preclinical and clinical activities, the Company is evaluating the impact that BET inhibitor compounds have on regulating pro-inflammatory cytokines.
Ticker SymbolVYNE
CompanyVyne Therapeutics Inc
CEODomzalski (David)
Websitehttps://vynetherapeutics.com/
Shareholders
FAQs
What is the current price of Vyne Therapeutics Inc (VYNE)?
The current price of Vyne Therapeutics Inc (VYNE) is 28.56.
What is the symbol of Vyne Therapeutics Inc?
The ticker symbol of Vyne Therapeutics Inc is VYNE.
What is the 52-week high of Vyne Therapeutics Inc?
The 52-week high of Vyne Therapeutics Inc is 1.96.
What is the 52-week low of Vyne Therapeutics Inc?
The 52-week low of Vyne Therapeutics Inc is 0.28.
What is the market capitalization of Vyne Therapeutics Inc?
The market capitalization of Vyne Therapeutics Inc is 18.71M.
What is the Earnings Per Share (EPS TTM) of Vyne Therapeutics Inc (VYNE)?
The Earnings Per Share (EPS TTM) of Vyne Therapeutics Inc (VYNE) is -0.62.
